- Home
- Publications
- Publication Search
- Publication Details
Title
Myelofibrosis biology and contemporary management
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-03-21
DOI
10.1111/bjh.16576
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis
- (2020) John Mascarenhas et al. BLOOD
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
- (2020) Claire N Harrison et al. BLOOD
- Analysis of Metformin Effects on Bone Marrow Fibrosis and Disease Progression in Primary Myelofibrosis Patients: Preliminary Results of an Open Label Phase II Trial (FIBROMET)
- (2020) Paula De Melo Campos et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- A Phase 2a Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Myelofibrosis
- (2020) Kristen Pettit et al. BLOOD
- Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib
- (2020) Aaron T. Gerds et al. BLOOD
- Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia
- (2019) Antonio Piga et al. BLOOD
- ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis
- (2019) Ying Guo et al. LEUKEMIA
- Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
- (2019) Rangit R. Vallapureddy et al. Blood Cancer Journal
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
- (2019) Natasha Szuber et al. MAYO CLINIC PROCEEDINGS
- State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
- (2019) Donal P. McLornan et al. HAEMATOLOGICA
- Comments on pre-fibrotic myelofibrosis and how should it be managed
- (2019) Tiziano Barbui et al. BRITISH JOURNAL OF HAEMATOLOGY
- Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
- (2019) Nico Gagelmann et al. BLOOD
- Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants
- (2019) Christian Pecquet et al. BLOOD
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Mutated CALR: tails from the crypt
- (2019) Jerry L. Spivak BLOOD
- Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo
- (2019) Brittany Woods et al. CLINICAL CANCER RESEARCH
- Mutant calreticulin in myeloproliferative neoplasms
- (2019) Joan How et al. BLOOD
- Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX
- (2019) Claire N Harrison et al. BLOOD
- Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count
- (2019) Claire N Harrison et al. BLOOD
- Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis
- (2019) Lucia Masarova et al. BLOOD
- JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2 V617F mutated disease
- (2018) Ayalew Tefferi et al. AMERICAN JOURNAL OF HEMATOLOGY
- How we treat myelofibrosis after failure of JAK inhibitors
- (2018) Animesh Pardanani et al. BLOOD
- MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis
- (2018) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
- (2018) Paola Guglielmelli et al. JOURNAL OF CLINICAL ONCOLOGY
- Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
- (2018) Maura Nicolosi et al. LEUKEMIA
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients
- (2018) Ayalew Tefferi et al. LEUKEMIA
- U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions
- (2018) Ayalew Tefferi et al. LEUKEMIA
- Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
- (2018) Ayalew Tefferi et al. LEUKEMIA
- GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
- (2018) Ayalew Tefferi et al. LEUKEMIA
- The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
- (2018) Tiziano Barbui et al. Blood Cancer Journal
- Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
- (2018) Claire N Harrison et al. Lancet Haematology
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
- (2018) John Mascarenhas et al. JAMA Oncology
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis
- (2018) Anna Chorzalska et al. BLOOD
- Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
- (2018) Sebastien Jacquelin et al. BLOOD
- Determinants of long-term outcome in type 1 calreticulin-mutated myelofibrosis
- (2018) Natasha Szuber et al. LEUKEMIA
- Classification and Personalized Prognosis in Myeloproliferative Neoplasms
- (2018) Jacob Grinfeld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
- (2017) Laure Gilles et al. JOURNAL OF CLINICAL INVESTIGATION
- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis
- (2017) A Pardanani et al. LEUKEMIA
- Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis
- (2017) A Tefferi et al. LEUKEMIA
- A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
- (2017) F Passamonti et al. LEUKEMIA
- Genetic Risk Assessment in Myeloproliferative Neoplasms
- (2017) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- The thrombopoietin/MPL axis is activated in the Gata1low mouse model of myelofibrosis and is associated with a defective RPS14 signature
- (2017) M Zingariello et al. Blood Cancer Journal
- miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
- (2017) Sebastiano Rontauroli et al. Oncotarget
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm
- (2016) Yue Yang et al. BLOOD
- Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
- (2016) M. Araki et al. BLOOD
- Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
- (2016) William Vainchenker et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis
- (2016) Jean Grisouard et al. BLOOD
- JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms
- (2016) Chi Hua Sarah Lin et al. BLOOD CELLS MOLECULES AND DISEASES
- Loss ofEzh2synergizes withJAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
- (2016) Takafumi Shimizu et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
- (2016) D A C Fisher et al. LEUKEMIA
- Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis
- (2016) Vittorio Abbonante et al. STEM CELLS
- Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
- (2016) S. Elf et al. Cancer Discovery
- Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants
- (2015) I. Chachoua et al. BLOOD
- Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis
- (2015) C. Marty et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells
- (2015) Paola Guglielmelli et al. PLoS One
- Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex
- (2015) Anand Balasubramani et al. Nature Communications
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis
- (2014) R. Norfo et al. BLOOD
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms
- (2014) Lorena Arranz et al. NATURE
- Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells
- (2014) Meng Zhao et al. NATURE MEDICINE
- Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion
- (2014) Ingmar Bruns et al. NATURE MEDICINE
- AKT is a therapeutic target in myeloproliferative neoplasms
- (2013) I Khan et al. LEUKEMIA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Megakaryocytes Contribute to the Bone Marrow-Matrix Environment by Expressing Fibronectin, Type IV Collagen, and Laminin
- (2013) Alessandro Malara et al. STEM CELLS
- SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
- (2012) T. L. Lasho et al. BLOOD
- ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
- (2012) Omar Abdel-Wahab et al. CANCER CELL
- One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
- (2012) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- EZH2 mutational status predicts poor survival in myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- How I treat myelofibrosis
- (2011) A. Tefferi BLOOD
- Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
- (2011) F. Passamonti et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
- (2011) A Tefferi et al. LEUKEMIA
- DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms
- (2011) O Abdel-Wahab et al. LEUKEMIA
- Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
- (2011) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone Marrow Morphologic Features in Polycythemia Vera WithJAK2Exon 12 Mutations
- (2010) Meredith A. Lakey et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Mesenchymal and haematopoietic stem cells form a unique bone marrow niche
- (2010) Simón Méndez-Ferrer et al. NATURE
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia
- (2009) Kais Hussein et al. PLATELETS
- Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis
- (2009) Lilian Varricchio et al. Expert Review of Hematology
- Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
- (2008) Oliver Bock et al. AMERICAN JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now